WAT:NYSEWaters Corporation Analysis

Waters Corporation posted Q4 2025 revenue of $932 million, hitting the top of its guidance range and delivering a 7% year‑over‑year increase, underscoring resilient demand for its chromatography and mass‑spectrometry platforms. Operating margin stands at 33.8% and ROE at 29.3%, reflecting a high‑margin, cash‑generative business with $0.43 billion free cash flow. However, the stock trades at a trailing P/E of 27.8x versus an industry average of 25.2x and a price‑to‑book of 6.97x, while the DCF fair value estimate of $71.2 is dramatically below the current market price of $299.63, indicating significant overvaluation. Technical indicators are mixed: the 20‑day SMA (≈$319) sits above price, the 14‑day RSI is near 30 suggesting oversold conditions, and the MACD remains bearish, yet volume is decreasing, hinting at limited upside momentum. The market sentiment is extremely bullish (Fear‑Greed Index 76.9), but the 30‑day volatility of ~51% and beta around 1.0 imply heightened price swings. Recent product launches such as the ARES‑G3™ Rheometer could fuel incremental growth, but short‑term price action is likely constrained by the strong resistance near $338 and the proximity to a support level around $296. Overall, the fundamentals are solid, but valuation and technical signals advise caution.